|
G |
Alb |
albumin |
affects binding |
ISO |
Acetohexamide binds to ALB protein; Acetohexamide binds to ALB protein modified form |
CTD |
PMID:20435530 PMID:20829128 PMID:20956006 PMID:20974553 PMID:21612784 |
|
NCBI chr 5:90,608,729...90,624,461
Ensembl chr 5:90,608,756...90,624,461
|
|
G |
Dhrs3 |
dehydrogenase/reductase 3 |
increases metabolic processing |
ISO |
DHRS3 protein results in increased metabolism of Acetohexamide |
CTD |
PMID:25451588 |
|
NCBI chr 4:144,618,712...144,654,214
Ensembl chr 4:144,619,397...144,654,779
|
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity |
ISO |
methyl bensulfuron results in increased activity of NR1I2 protein |
CTD |
PMID:22206814 |
|
NCBI chr16:38,068,711...38,115,211
Ensembl chr16:38,068,685...38,115,186
|
|
|
G |
Abcc8 |
ATP-binding cassette, sub-family C member 8 |
multiple interactions |
ISO |
[KCNJ11 mutant form co-treated with ABCC8 mutant form] results in decreased susceptibility to Chlorpropamide |
CTD |
PMID:22209866 |
|
NCBI chr 7:45,753,952...45,829,441
Ensembl chr 7:45,753,947...45,829,457
|
|
G |
Ace2 |
angiotensin converting enzyme 2 |
decreases expression |
ISO |
Chlorpropamide results in decreased expression of ACE2 mRNA |
CTD |
PMID:32808185 |
|
NCBI chr X:162,922,338...162,971,414
Ensembl chr X:162,922,328...162,971,416
|
|
G |
Avp |
arginine vasopressin |
decreases secretion |
ISO |
Chlorpropamide results in decreased secretion of AVP protein modified form |
CTD |
PMID:5029389 |
|
NCBI chr 2:130,422,540...130,424,508
Ensembl chr 2:130,422,540...130,424,474
|
|
G |
Fos |
FBJ osteosarcoma oncogene |
increases expression |
ISO |
Chlorpropamide results in increased expression of FOS mRNA |
CTD |
PMID:12730611 |
|
NCBI chr12:85,520,664...85,524,048
Ensembl chr12:85,520,664...85,524,047
|
|
G |
Ins2 |
insulin II |
decreases expression increases expression multiple interactions |
ISO |
Chlorpropamide results in decreased expression of INS protein Chlorpropamide results in increased expression of INS mRNA Chlorpropamide inhibits the reaction [Glucose results in decreased secretion of INS protein] |
CTD |
PMID:15642492 |
|
NCBI chr 7:142,232,393...142,233,463
Ensembl chr 7:142,232,393...142,297,118
|
|
G |
Kcnj11 |
potassium inwardly rectifying channel, subfamily J, member 11 |
multiple interactions |
ISO |
[KCNJ11 mutant form co-treated with ABCC8 mutant form] results in decreased susceptibility to Chlorpropamide |
CTD |
PMID:22209866 |
|
NCBI chr 7:45,746,545...45,750,215
Ensembl chr 7:45,743,377...45,750,188
|
|
|
G |
Abcc8 |
ATP-binding cassette, sub-family C member 8 |
multiple interactions |
ISO |
[KCNJ11 mutant form co-treated with ABCC8 mutant form] results in increased susceptibility to Gliclazide |
CTD |
PMID:22209866 |
|
NCBI chr 7:45,753,952...45,829,441
Ensembl chr 7:45,753,947...45,829,457
|
|
G |
Akr1c18 |
aldo-keto reductase family 1, member C18 |
decreases activity |
ISO |
Gliclazide results in decreased activity of AKR1C3 protein |
CTD |
PMID:26362498 |
|
NCBI chr13:4,182,614...4,200,645
Ensembl chr13:4,182,614...4,200,653
|
|
G |
Alb |
albumin |
affects binding multiple interactions |
ISO |
Gliclazide binds to ALB protein Gliclazide inhibits the reaction [[Streptozocin co-treated with Cholesterol, Dietary] results in increased secretion of ALB protein] |
CTD |
PMID:14871415 PMID:20974553 |
|
NCBI chr 5:90,608,729...90,624,461
Ensembl chr 5:90,608,756...90,624,461
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
multiple interactions |
ISO |
Gliclazide inhibits the reaction [Glucose results in decreased expression of BCL2 protein] |
CTD |
PMID:18088078 |
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Casp3 |
caspase 3 |
multiple interactions decreases expression |
ISO |
Gliclazide inhibits the reaction [Glucose results in increased expression of CASP3 protein] Gliclazide results in decreased expression of CASP3 mRNA Gliclazide inhibits the reaction [Acetic Acid results in increased expression of CASP3 protein] |
CTD |
PMID:18088078 PMID:32045587 PMID:33652124 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of CAT protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; Gliclazide inhibits the reaction [Streptozocin results in decreased activity of CAT protein] |
CTD |
PMID:20307516 PMID:20643114 PMID:21439372 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Cdkn1a |
cyclin dependent kinase inhibitor 1A |
multiple interactions |
EXP |
Gliclazide inhibits the reaction [Hydrogen Peroxide results in increased expression of CDKN1A mRNA] |
CTD |
PMID:12646174 |
|
NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701
|
|
G |
G6pdx |
glucose-6-phosphate dehydrogenase X-linked |
multiple interactions |
ISO |
Gliclazide inhibits the reaction [Streptozocin results in decreased activity of G6PD protein] |
CTD |
PMID:28330423 |
|
NCBI chr X:73,453,089...73,472,486
Ensembl chr X:73,453,089...73,472,800
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions |
ISO |
Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC mRNA]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC protein] |
CTD |
PMID:21439372 |
|
NCBI chr 9:77,661,817...77,701,771
Ensembl chr 9:77,661,817...77,701,767
|
|
G |
Glo1 |
glyoxalase 1 |
multiple interactions |
ISO |
Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of GLO1 protein] |
CTD |
PMID:21439372 |
|
NCBI chr17:30,811,835...30,831,633
Ensembl chr17:30,803,910...30,845,845
|
|
G |
Gsr |
glutathione reductase |
multiple interactions |
ISO |
Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of GSR protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of GSR protein] |
CTD |
PMID:20307516 PMID:21439372 |
|
NCBI chr 8:34,143,266...34,188,190
Ensembl chr 8:34,142,551...34,188,191
|
|
G |
Gstm5 |
glutathione S-transferase, mu 5 |
multiple interactions |
ISO |
Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GSTM3 mRNA] |
CTD |
PMID:21439372 |
|
NCBI chr 3:107,803,240...107,806,002
Ensembl chr 3:107,803,137...107,806,002
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
EXP ISO |
Gliclazide inhibits the reaction [Hydrogen Peroxide results in increased expression of HMOX1 mRNA] Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of HMOX1 protein] |
CTD |
PMID:12646174 PMID:21439372 |
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
Gliclazide inhibits the reaction [[Streptozocin co-treated with Cholesterol, Dietary] results in increased expression of ICAM1 protein]; Gliclazide inhibits the reaction [Acetic Acid results in increased expression of ICAM1 protein] |
CTD |
PMID:14871415 PMID:32045587 |
|
NCBI chr 9:20,927,236...20,940,110
Ensembl chr 9:20,927,281...20,940,113
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
Gliclazide inhibits the reaction [Acetic Acid results in decreased expression of IL10 protein] |
CTD |
PMID:32045587 |
|
NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of IL1B protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of IL1B protein]; Gliclazide inhibits the reaction [Streptozocin results in increased expression of IL1B protein] |
CTD |
PMID:20307516 PMID:20643114 PMID:21439372 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of IL6 protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of IL6 protein]; Gliclazide inhibits the reaction [Acetic Acid results in increased expression of IL6 protein]; Gliclazide inhibits the reaction [Streptozocin results in increased expression of IL6 protein] |
CTD |
PMID:20307516 PMID:20643114 PMID:21439372 PMID:32045587 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Ins1 |
insulin I |
multiple interactions |
ISO |
Gliclazide inhibits the reaction [Streptozocin results in decreased expression of and results in decreased secretion of INS1 protein]; Gliclazide inhibits the reaction [Streptozocin results in decreased expression of INS1 protein] |
CTD |
PMID:28330423 PMID:28625491 |
|
NCBI chr19:52,252,735...52,253,453
Ensembl chr19:52,252,735...52,253,914
|
|
G |
Kcnj11 |
potassium inwardly rectifying channel, subfamily J, member 11 |
multiple interactions |
ISO |
[KCNJ11 mutant form co-treated with ABCC8 mutant form] results in increased susceptibility to Gliclazide |
CTD |
PMID:22209866 |
|
NCBI chr 7:45,746,545...45,750,215
Ensembl chr 7:45,743,377...45,750,188
|
|
G |
Keap1 |
kelch-like ECH-associated protein 1 |
multiple interactions |
ISO |
Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 mRNA]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 protein] |
CTD |
PMID:21439372 |
|
NCBI chr 9:21,141,026...21,150,628
Ensembl chr 9:21,141,026...21,150,657
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
multiple interactions |
ISO |
Gliclazide inhibits the reaction [Acetic Acid results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:32045587 |
|
NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
multiple interactions |
ISO |
Gliclazide inhibits the reaction [Acetic Acid results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:32045587 |
|
NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
Gliclazide inhibits the reaction [Acetic Acid results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:32045587 |
|
NCBI chr14:33,099,855...33,169,213
Ensembl chr14:33,099,855...33,169,115
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
Gliclazide inhibits the reaction [Acetic Acid results in increased activity of MPO protein] |
CTD |
PMID:32045587 |
|
NCBI chr11:87,684,610...87,695,238
Ensembl chr11:87,684,407...87,695,239
|
|
G |
Ncf1 |
neutrophil cytosolic factor 1 |
multiple interactions |
ISO |
Gliclazide inhibits the reaction [[Streptozocin co-treated with Cholesterol, Dietary] results in increased expression of NCF1 protein] |
CTD |
PMID:14871415 |
|
NCBI chr 5:134,248,907...134,258,479
Ensembl chr 5:134,248,907...134,258,479
|
|
G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
multiple interactions |
ISO |
Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 mRNA]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 protein] |
CTD |
PMID:21439372 |
|
NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985
|
|
G |
Nos3 |
nitric oxide synthase 3, endothelial cell |
increases expression |
ISO |
Gliclazide results in increased expression of NOS3 protein |
CTD |
PMID:14871415 |
|
NCBI chr 5:24,569,772...24,589,472
Ensembl chr 5:24,569,808...24,589,472
|
|
G |
Pparg |
peroxisome proliferator activated receptor gamma |
multiple interactions |
ISO |
Gliclazide inhibits the reaction [Acetic Acid results in decreased expression of PPARG protein] |
CTD |
PMID:32045587 |
|
NCBI chr 6:115,337,828...115,467,365
Ensembl chr 6:115,337,912...115,467,360
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
multiple interactions |
ISO |
Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of RELA protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of RELA protein]; Gliclazide inhibits the reaction [Streptozocin results in increased expression of RELA protein] |
CTD |
PMID:20307516 PMID:20643114 PMID:21439372 |
|
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
|
|
G |
Sod2 |
superoxide dismutase 2, mitochondrial |
multiple interactions |
ISO |
Gliclazide inhibits the reaction [[Streptozocin co-treated with Cholesterol, Dietary] results in decreased expression of SOD2 protein] |
CTD |
PMID:14871415 |
|
NCBI chr17:13,226,726...13,237,006
Ensembl chr17:13,225,733...13,258,950
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases expression |
ISO |
Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of TNF protein]; Gliclazide inhibits the reaction [Streptozocin results in increased expression of TNF protein] Gliclazide results in decreased expression of TNF protein |
CTD |
PMID:20307516 PMID:20643114 PMID:21439372 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Tnfaip3 |
tumor necrosis factor, alpha-induced protein 3 |
multiple interactions |
EXP |
Gliclazide inhibits the reaction [Hydrogen Peroxide results in increased expression of TNFAIP3 mRNA] |
CTD |
PMID:12646174 |
|
NCBI chr10:18,876,658...18,891,158
Ensembl chr10:18,876,658...18,891,405
|
|
G |
Trp53 |
transformation related protein 53 |
increases expression |
ISO |
Gliclazide results in increased expression of TP53 mRNA |
CTD |
PMID:33652124 |
|
NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699
|
|
|
G |
Abcb11 |
ATP-binding cassette, sub-family B member 11 |
decreases activity multiple interactions |
ISO |
glimepiride results in decreased activity of ABCB11 protein glimepiride inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] |
CTD |
PMID:20829430 PMID:23956101 PMID:24014644 |
|
NCBI chr 2:69,068,626...69,172,960
Ensembl chr 2:69,068,626...69,172,958
|
|
G |
Abcc8 |
ATP-binding cassette, sub-family C member 8 |
multiple interactions |
ISO |
[KCNJ11 mutant form co-treated with ABCC8 mutant form] results in decreased susceptibility to glimepiride |
CTD |
PMID:22209866 |
|
NCBI chr 7:45,753,952...45,829,441
Ensembl chr 7:45,753,947...45,829,457
|
|
G |
Akr1c18 |
aldo-keto reductase family 1, member C18 |
decreases activity |
ISO |
glimepiride results in decreased activity of AKR1C3 protein |
CTD |
PMID:26362498 |
|
NCBI chr13:4,182,614...4,200,645
Ensembl chr13:4,182,614...4,200,653
|
|
G |
Akr1c20 |
aldo-keto reductase family 1, member C20 |
decreases activity |
ISO |
glimepiride results in decreased activity of AKR1C1 protein |
CTD |
PMID:26362498 |
|
NCBI chr13:4,536,855...4,573,353
Ensembl chr13:4,536,848...4,573,344
|
|
G |
Capn1 |
calpain 1 |
increases expression |
ISO |
glimepiride results in increased expression of CAPN1 mRNA |
CTD |
PMID:33652124 |
|
NCBI chr19:6,038,573...6,065,855
Ensembl chr19:6,038,573...6,065,927
|
|
G |
Capn10 |
calpain 10 |
increases expression |
ISO |
glimepiride results in increased expression of CAPN10 mRNA |
CTD |
PMID:33652124 |
|
NCBI chr 1:92,862,130...92,875,670
Ensembl chr 1:92,862,098...92,875,663
|
|
G |
Capn2 |
calpain 2 |
increases expression |
ISO |
glimepiride results in increased expression of CAPN2 mRNA |
CTD |
PMID:33652124 |
|
NCBI chr 1:182,294,818...182,345,175
Ensembl chr 1:182,294,825...182,345,173
|
|
G |
Casp3 |
caspase 3 |
increases expression increases activity |
ISO |
glimepiride results in increased expression of CASP3 mRNA glimepiride results in increased activity of CASP3 protein |
CTD |
PMID:33652124 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
H2-M3 |
histocompatibility 2, M region locus 3 |
affects expression |
ISO |
glimepiride affects the expression of HLA-G mRNA |
CTD |
PMID:25811541 |
|
NCBI chr17:37,581,094...37,585,380
Ensembl chr17:37,581,111...37,585,375
|
|
G |
Ins1 |
insulin I |
multiple interactions |
ISO |
[Plant Extracts co-treated with glimepiride] inhibits the reaction [Streptozocin results in decreased expression of INS1 protein]; glimepiride inhibits the reaction [Streptozocin results in decreased expression of INS1 protein] |
CTD |
PMID:26721197 |
|
NCBI chr19:52,252,735...52,253,453
Ensembl chr19:52,252,735...52,253,914
|
|
G |
Ins2 |
insulin II |
decreases expression |
ISO |
glimepiride results in decreased expression of INS protein |
CTD |
PMID:15642492 |
|
NCBI chr 7:142,232,393...142,233,463
Ensembl chr 7:142,232,393...142,297,118
|
|
G |
Kcnj11 |
potassium inwardly rectifying channel, subfamily J, member 11 |
multiple interactions |
ISO |
[KCNJ11 mutant form co-treated with ABCC8 mutant form] results in decreased susceptibility to glimepiride |
CTD |
PMID:22209866 |
|
NCBI chr 7:45,746,545...45,750,215
Ensembl chr 7:45,743,377...45,750,188
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity multiple interactions |
ISO |
glimepiride results in increased activity of NR1I2 protein [glimepiride results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA |
CTD |
PMID:25455453 |
|
NCBI chr16:38,068,711...38,115,211
Ensembl chr16:38,068,685...38,115,186
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family, member 1b2 |
multiple interactions |
ISO |
glimepiride affects the reaction [SLCO1B3 protein results in increased uptake of Atorvastatin]; glimepiride affects the reaction [SLCO1B3 protein results in increased uptake of Sulfobromophthalein] |
CTD |
PMID:23121773 |
|
NCBI chr 6:141,575,178...141,632,372
Ensembl chr 6:141,575,244...141,632,372
|
|
G |
Slco2b1 |
solute carrier organic anion transporter family, member 2b1 |
multiple interactions |
ISO |
glimepiride inhibits the reaction [SLCO2B1 protein results in increased uptake of Atorvastatin]; glimepiride inhibits the reaction [SLCO2B1 protein results in increased uptake of Sulfobromophthalein] |
CTD |
PMID:23121773 |
|
NCBI chr 7:99,307,011...99,360,547
Ensembl chr 7:99,307,011...99,360,547
|
|
G |
Trp53 |
transformation related protein 53 |
increases expression |
ISO |
glimepiride results in increased expression of TP53 mRNA |
CTD |
PMID:33652124 |
|
NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699
|
|
|
G |
Abcb11 |
ATP-binding cassette, sub-family B member 11 |
multiple interactions decreases activity |
ISO |
Glipizide inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] Glipizide results in decreased activity of ABCB11 protein |
CTD |
PMID:24014644 |
|
NCBI chr 2:69,068,626...69,172,960
Ensembl chr 2:69,068,626...69,172,958
|
|
G |
Akr1c18 |
aldo-keto reductase family 1, member C18 |
decreases activity |
ISO |
Glipizide results in decreased activity of AKR1C3 protein |
CTD |
PMID:26362498 |
|
NCBI chr13:4,182,614...4,200,645
Ensembl chr13:4,182,614...4,200,653
|
|
G |
Akr1c20 |
aldo-keto reductase family 1, member C20 |
decreases activity |
ISO |
Glipizide results in decreased activity of AKR1C1 protein |
CTD |
PMID:26362498 |
|
NCBI chr13:4,536,855...4,573,353
Ensembl chr13:4,536,848...4,573,344
|
|
G |
Akr1c21 |
aldo-keto reductase family 1, member C21 |
decreases activity |
ISO |
Glipizide results in decreased activity of AKR1C2 protein |
CTD |
PMID:26362498 |
|
NCBI chr13:4,624,074...4,636,542
Ensembl chr13:4,624,074...4,636,540
|
|
G |
Cyp2c65 |
cytochrome P450, family 2, subfamily c, polypeptide 65 |
increases metabolic processing decreases metabolic processing |
ISO |
CYP2C9 protein results in increased metabolism of Glipizide CYP2C9 gene polymorphism results in decreased metabolism of Glipizide |
CTD |
PMID:10208645 |
|
NCBI chr19:39,049,450...39,082,392
Ensembl chr19:39,049,459...39,082,388
|
|
|
G |
Abcb11 |
ATP-binding cassette, sub-family B member 11 |
multiple interactions increases expression decreases activity |
ISO EXP |
[Glyburide results in decreased activity of ABCB11 protein] which results in decreased export of Taurodeoxycholic Acid; Glyburide inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] [Bile Acids and Salts co-treated with Glyburide] results in decreased expression of ABCB11 mRNA Glyburide results in increased expression of ABCB11 mRNA [Glyburide results in decreased activity of ABCB11 protein] which results in decreased export of Taurodeoxycholic Acid; [Glyburide results in decreased activity of ABCB11 protein] which results in decreased secretion of Rosuvastatin Calcium |
CTD |
PMID:11343252 PMID:15465654 PMID:15618715 PMID:19853032 PMID:20147439 PMID:20829430 PMID:23956101 PMID:24014644 PMID:27765674 PMID:31348918 PMID:35708773 More...
|
|
NCBI chr 2:69,068,626...69,172,960
Ensembl chr 2:69,068,626...69,172,958
|
|
G |
Abcb4 |
ATP-binding cassette, sub-family B member 4 |
increases expression |
ISO |
Glyburide results in increased expression of ABCB4 mRNA |
CTD |
PMID:27765674 |
|
NCBI chr 5:8,943,614...9,009,226
Ensembl chr 5:8,943,717...9,009,231
|
|
G |
Abcc1 |
ATP-binding cassette, sub-family C member 1 |
decreases activity |
ISO |
Glyburide results in decreased activity of ABCC1 protein |
CTD |
PMID:15652236 |
|
NCBI chr16:14,179,317...14,292,743
Ensembl chr16:14,179,422...14,293,601
|
|
G |
Abcc2 |
ATP-binding cassette, sub-family member 2 |
increases expression |
ISO EXP |
Glyburide results in increased expression of ABCC2 mRNA |
CTD |
PMID:27765674 PMID:35708773 |
|
NCBI chr19:43,770,747...43,826,771
Ensembl chr19:43,770,631...43,829,179
|
|
G |
Abcc3 |
ATP-binding cassette, sub-family C member 3 |
increases expression |
ISO |
Glyburide results in increased expression of ABCC3 mRNA |
CTD |
PMID:27765674 |
|
NCBI chr11:94,234,121...94,283,843
Ensembl chr11:94,234,121...94,283,823
|
|
G |
Abcc4 |
ATP-binding cassette, sub-family C member 4 |
increases expression |
EXP |
Glyburide results in increased expression of ABCC4 mRNA |
CTD |
PMID:35708773 |
|
NCBI chr14:118,720,104...118,945,475
Ensembl chr14:118,720,104...118,943,631
|
|
G |
Abcc8 |
ATP-binding cassette, sub-family C member 8 |
increases response to substance affects binding multiple interactions |
ISO |
ABCC8 protein results in increased susceptibility to Glyburide Glyburide binds to ABCC8 protein; Glyburide binds to ABCC8 protein mutant form Adenosine Triphosphate deficiency inhibits the reaction [Estradiol inhibits the reaction [Glyburide binds to ABCC8 protein]]; Estradiol inhibits the reaction [Glyburide binds to ABCC8 protein mutant form]; Estradiol inhibits the reaction [Glyburide binds to ABCC8 protein]; resveratrol inhibits the reaction [Glyburide binds to ABCC8 protein] |
CTD |
PMID:17138562 PMID:19095654 |
|
NCBI chr 7:45,753,952...45,829,441
Ensembl chr 7:45,753,947...45,829,457
|
|
G |
Abcc9 |
ATP-binding cassette, sub-family C member 9 |
affects binding decreases activity multiple interactions |
EXP |
Glyburide binds to ABCC9 protein mutant form Glyburide results in decreased activity of ABCC9 protein [Glyburide results in decreased activity of ABCC9 protein] which results in increased expression of XDH protein; Estradiol inhibits the reaction [Glyburide binds to ABCC9 protein mutant form]; Glyburide inhibits the reaction [[Oligomycins co-treated with Deoxyglucose] results in increased activity of [KCNJ11 protein binds to ABCC9 protein]]; resveratrol inhibits the reaction [Glyburide binds to ABCC9 protein] |
CTD |
PMID:17138562 PMID:19095654 PMID:22622455 PMID:28842488 |
|
NCBI chr 6:142,533,592...142,648,472
Ensembl chr 6:142,533,588...142,648,041
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 (Junior blood group) |
decreases export multiple interactions increases export |
ISO |
ABCG2 protein polymorphism results in decreased export of Glyburide 3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester inhibits the reaction [ABCG2 protein results in increased export of Glyburide]; 3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester promotes the reaction [ABCG2 protein polymorphism results in decreased export of Glyburide]; Genistein inhibits the reaction [ABCG2 protein results in increased export of Glyburide]; Genistein promotes the reaction [ABCG2 protein polymorphism results in decreased export of Glyburide] |
CTD |
PMID:26850786 |
|
NCBI chr 6:58,561,476...58,669,436
Ensembl chr 6:58,561,508...58,672,661
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
increases expression |
ISO |
Glyburide results in increased expression of ABCG5 mRNA |
CTD |
PMID:27765674 |
|
NCBI chr17:84,965,602...84,990,439
Ensembl chr17:84,965,662...84,990,439
|
|
G |
Ace2 |
angiotensin converting enzyme 2 |
decreases expression |
ISO |
Glyburide results in decreased expression of ACE2 mRNA |
CTD |
PMID:32808185 |
|
NCBI chr X:162,922,338...162,971,414
Ensembl chr X:162,922,328...162,971,416
|
|
G |
Acta2 |
actin alpha 2, smooth muscle, aorta |
multiple interactions |
ISO |
Glyburide promotes the reaction [Isoproterenol results in increased expression of ACTA2 protein]; pyrvinium inhibits the reaction [Glyburide promotes the reaction [Isoproterenol results in increased expression of ACTA2 protein]] |
CTD |
PMID:35305975 |
|
NCBI chr19:34,217,736...34,232,985
Ensembl chr19:34,218,490...34,232,990
|
|
G |
Ager |
advanced glycosylation end product-specific receptor |
multiple interactions |
ISO |
[Glyburide co-treated with Dimethyl Fumarate] inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of AGER protein]; Glyburide inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of AGER protein] |
CTD |
PMID:36999408 |
|
NCBI chr17:34,816,545...34,819,911
Ensembl chr17:34,816,836...34,819,910
|
|
G |
Ahr |
aryl-hydrocarbon receptor |
multiple interactions |
ISO |
Glyburide inhibits the reaction [Tetrachlorodibenzodioxin binds to AHR protein] |
CTD |
PMID:10799337 |
|
NCBI chr12:35,547,978...35,584,988
Ensembl chr12:35,547,973...35,585,037
|
|
G |
Aif1 |
allograft inflammatory factor 1 |
multiple interactions |
ISO EXP |
Glyburide inhibits the reaction [2,5-hexanedione results in increased expression of AIF1 protein] Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of AIF1 protein] |
CTD |
PMID:32375810 PMID:32522579 PMID:32860822 |
|
NCBI chr17:35,389,967...35,394,977
Ensembl chr17:35,389,967...35,395,044
|
|
G |
Akr1c18 |
aldo-keto reductase family 1, member C18 |
decreases activity |
ISO |
Glyburide results in decreased activity of AKR1C3 protein |
CTD |
PMID:26362498 |
|
NCBI chr13:4,182,614...4,200,645
Ensembl chr13:4,182,614...4,200,653
|
|
G |
Akr1c20 |
aldo-keto reductase family 1, member C20 |
decreases activity |
ISO |
Glyburide results in decreased activity of AKR1C1 protein |
CTD |
PMID:26362498 |
|
NCBI chr13:4,536,855...4,573,353
Ensembl chr13:4,536,848...4,573,344
|
|
G |
Akr1c21 |
aldo-keto reductase family 1, member C21 |
decreases activity |
ISO |
Glyburide results in decreased activity of AKR1C2 protein |
CTD |
PMID:26362498 |
|
NCBI chr13:4,624,074...4,636,542
Ensembl chr13:4,624,074...4,636,540
|
|
G |
Akt1 |
thymoma viral proto-oncogene 1 |
multiple interactions |
ISO |
Glyburide inhibits the reaction [sodium bisulfide results in increased phosphorylation of AKT1 protein]; Glyburide inhibits the reaction [Streptozocin results in decreased expression of AKT1 protein] |
CTD |
PMID:21800153 PMID:33724628 |
|
NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318
|
|
G |
Alb |
albumin |
affects binding |
ISO |
Glyburide binds to ALB protein |
CTD |
PMID:20974553 |
|
NCBI chr 5:90,608,729...90,624,461
Ensembl chr 5:90,608,756...90,624,461
|
|
G |
Apoa1 |
apolipoprotein A-I |
multiple interactions |
ISO |
Glyburide promotes the reaction [1,2-linoleoylphosphatidylcholine results in increased secretion of APOA1 protein]; Glyburide promotes the reaction [Clofibrate results in increased secretion of APOA1 protein] |
CTD |
PMID:19717637 |
|
NCBI chr 9:46,139,928...46,141,767
Ensembl chr 9:46,139,878...46,141,764
|
|
G |
Arg1 |
arginase, liver |
multiple interactions |
ISO EXP |
Glyburide inhibits the reaction [2,5-hexanedione results in decreased expression of ARG1 mRNA] Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of ARG1 mRNA] |
CTD |
PMID:32522579 PMID:32860822 PMID:34052309 |
|
NCBI chr10:24,791,105...24,803,368
Ensembl chr10:24,791,119...24,803,382
|
|
G |
Bax |
BCL2-associated X protein |
multiple interactions |
ISO |
Glyburide inhibits the reaction [Streptozocin results in increased expression of BAX protein] |
CTD |
PMID:33724628 |
|
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
multiple interactions |
ISO |
Glyburide inhibits the reaction [sodium bisulfide results in increased expression of BCL2 protein]; Glyburide inhibits the reaction [Streptozocin results in decreased expression of BCL2 protein] |
CTD |
PMID:21800153 PMID:33724628 |
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Capn2 |
calpain 2 |
increases expression |
ISO |
Glyburide results in increased expression of CAPN2 mRNA |
CTD |
PMID:33652124 |
|
NCBI chr 1:182,294,818...182,345,175
Ensembl chr 1:182,294,825...182,345,173
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
ISO EXP |
[Glyburide co-treated with Dimethyl Fumarate] inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased cleavage of CASP1 protein]; Glyburide inhibits the reaction [2,5-hexanedione results in increased cleavage of CASP1 protein]; Glyburide inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased cleavage of CASP1 protein]; Glyburide inhibits the reaction [Paraquat results in increased expression of CASP1 protein] Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased cleavage of CASP1 protein]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased cleavage of CASP1 protein]; Glyburide inhibits the reaction [Ozone results in increased cleavage of CASP1 protein] |
CTD |
PMID:25338942 PMID:32167222 PMID:32375810 PMID:32522579 PMID:32860822 PMID:34052309 PMID:36999408 More...
|
|
NCBI chr 9:5,298,517...5,307,281
Ensembl chr 9:5,298,508...5,307,290
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity increases expression |
ISO |
Glyburide inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased activity of CASP3 protein]; Glyburide inhibits the reaction [Streptozocin results in increased expression of CASP3 protein]; Glyburide promotes the reaction [Isoproterenol results in increased activity of CASP3 protein]; pyrvinium inhibits the reaction [Glyburide promotes the reaction [Isoproterenol results in increased activity of CASP3 protein]] Glyburide results in increased activity of CASP3 protein Glyburide results in increased expression of CASP3 mRNA |
CTD |
PMID:16310184 PMID:33652124 PMID:35305975 PMID:36504472 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Cat |
catalase |
multiple interactions |
EXP ISO |
Glyburide inhibits the reaction [Streptozocin results in decreased expression of CAT protein] [Glyburide co-treated with Dimethyl Fumarate] inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in decreased expression of CAT protein]; Glyburide inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in decreased expression of CAT protein]; Glyburide inhibits the reaction [Streptozocin results in decreased activity of CAT protein]; Glyburide inhibits the reaction [Streptozocin results in decreased expression of CAT protein]; Glyburide promotes the reaction [Isoproterenol results in decreased activity of CAT protein]; pyrvinium inhibits the reaction [Glyburide promotes the reaction [Isoproterenol results in decreased activity of CAT protein]] |
CTD |
PMID:23716880 PMID:24760747 PMID:26700463 PMID:26748309 PMID:28757134 PMID:29223569 PMID:30582900 PMID:30817903 PMID:33724628 PMID:35305975 PMID:36999408 More...
|
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Cftr |
cystic fibrosis transmembrane conductance regulator |
multiple interactions decreases activity |
ISO EXP |
Glyburide binds to and results in decreased activity of CFTR protein; Glyburide inhibits the reaction [1-Octanol results in increased activity of CFTR protein]; Glyburide inhibits the reaction [[[Colforsin co-treated with Genistein] results in increased activity of CFTR protein] which results in increased transport of Iodides]; Glyburide inhibits the reaction [Colforsin results in increased activity of CFTR protein] Glyburide results in decreased activity of CFTR protein Glyburide inhibits the reaction [[Phenylephrine co-treated with 5-butyl-6-hydroxy-10-chlorobenzo(c)quinolizinium chloride] results in increased activity of CFTR protein] Glyburide inhibits the reaction [CFTR protein affects the transport of Bicarbonates]; Glyburide inhibits the reaction [CFTR protein affects the transport of Chlorides] |
CTD |
PMID:14502435 PMID:14967738 PMID:15131065 PMID:15236628 PMID:15371258 PMID:15389550 PMID:15634668 PMID:15650130 PMID:15654852 PMID:15802612 PMID:15857825 PMID:16012949 PMID:16054561 PMID:17596272 PMID:18230692 PMID:19061877 More...
|
|
NCBI chr 6:18,170,686...18,322,769
Ensembl chr 6:18,170,686...18,322,767
|
|
G |
Col1a1 |
collagen, type I, alpha 1 |
decreases expression |
EXP |
Glyburide results in decreased expression of COL1A1 mRNA |
CTD |
PMID:35708773 |
|
NCBI chr11:94,827,050...94,843,868
Ensembl chr11:94,827,050...94,843,868
|
|
G |
Cp |
ceruloplasmin |
multiple interactions |
ISO |
Glyburide inhibits the reaction [Streptozocin results in decreased expression of CP protein] |
CTD |
PMID:26748309 |
|
NCBI chr 3:20,011,097...20,063,914
Ensembl chr 3:20,011,218...20,063,309
|
|
G |
Cst3 |
cystatin C |
multiple interactions |
ISO |
Glyburide inhibits the reaction [Streptozocin results in increased expression of CST3 protein] |
CTD |
PMID:33387473 |
|
NCBI chr 2:148,713,642...148,717,432
Ensembl chr 2:148,713,642...148,717,612
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions |
ISO |
[Glyburide co-treated with Isoproterenol] results in increased expression of CTNNB1 mRNA; Glyburide promotes the reaction [Isoproterenol results in increased expression of CTNNB1 protein]; pyrvinium inhibits the reaction [[Glyburide co-treated with Isoproterenol] results in increased expression of CTNNB1 mRNA]; pyrvinium inhibits the reaction [Glyburide promotes the reaction [Isoproterenol results in increased expression of CTNNB1 protein]] |
CTD |
PMID:35305975 |
|
NCBI chr 9:120,762,466...120,789,573
Ensembl chr 9:120,758,282...120,789,573
|
|
G |
Cybb |
cytochrome b-245, beta polypeptide |
multiple interactions |
EXP |
Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CYBB protein]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYBB protein] |
CTD |
PMID:32375810 PMID:34052309 |
|
NCBI chr X:9,301,493...9,354,005
Ensembl chr X:9,301,491...9,354,010
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
Glyburide inhibits the reaction [Methylcholanthrene results in increased expression of CYP1A1 mRNA]; Glyburide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:10799337 |
|
NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
ISO |
Glyburide inhibits the reaction [natakalim inhibits the reaction [Isoproterenol results in increased expression of EDN1 mRNA]]; Glyburide inhibits the reaction [natakalim inhibits the reaction [Isoproterenol results in increased expression of EDN1 protein]] |
CTD |
PMID:27890915 |
|
NCBI chr13:42,454,952...42,461,466
Ensembl chr13:42,454,952...42,461,466
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions |
ISO |
Glyburide promotes the reaction [Isoproterenol results in increased expression of FN1 protein]; pyrvinium inhibits the reaction [Glyburide promotes the reaction [Isoproterenol results in increased expression of FN1 protein]] |
CTD |
PMID:35305975 |
|
NCBI chr 1:71,624,632...71,692,439
Ensembl chr 1:71,624,679...71,692,359
|
|
G |
Fth1 |
ferritin heavy polypeptide 1 |
multiple interactions |
EXP |
Glyburide inhibits the reaction [Lipopolysaccharides results in increased expression of FTH1 mRNA] |
CTD |
PMID:27246103 |
|
NCBI chr19:9,957,964...9,962,475
Ensembl chr19:9,957,962...9,962,462
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions |
ISO |
Glyburide inhibits the reaction [Streptozocin results in increased activity of G6PC1 protein] |
CTD |
PMID:25641191 |
|
NCBI chr11:101,258,542...101,268,729
Ensembl chr11:101,258,387...101,268,729
|
|
G |
G6pc3 |
glucose 6 phosphatase, catalytic, 3 |
multiple interactions |
ISO |
Glyburide inhibits the reaction [Streptozocin results in decreased activity of G6PC3 protein] |
CTD |
PMID:31345080 |
|
NCBI chr11:102,080,525...102,084,907
Ensembl chr11:102,080,446...102,084,907
|
|
G |
G6pdx |
glucose-6-phosphate dehydrogenase X-linked |
multiple interactions |
ISO |
Glyburide inhibits the reaction [Streptozocin results in decreased activity of G6PD protein] |
CTD |
PMID:25641191 PMID:31345080 |
|
NCBI chr X:73,453,089...73,472,486
Ensembl chr X:73,453,089...73,472,800
|
|
G |
Gpt |
glutamic pyruvic transaminase, soluble |
multiple interactions |
ISO |
Glyburide inhibits the reaction [Streptozocin results in increased activity of GPT protein] |
CTD |
PMID:29223569 |
|
NCBI chr15:76,580,926...76,583,875
Ensembl chr15:76,579,916...76,583,886
|
|
G |
Gsdmd |
gasdermin D |
multiple interactions |
ISO |
Glyburide inhibits the reaction [2,5-hexanedione results in increased cleavage of GSDMD protein] |
CTD |
PMID:32522579 PMID:32860822 |
|
NCBI chr15:75,733,990...75,739,257
Ensembl chr15:75,734,176...75,739,257
|
|
G |
Gsr |
glutathione reductase |
multiple interactions |
ISO |
Glyburide inhibits the reaction [Streptozocin results in decreased activity of GSR protein]; Glyburide inhibits the reaction [Streptozocin results in decreased expression of GSR protein] |
CTD |
PMID:26748309 PMID:33724628 |
|
NCBI chr 8:34,143,266...34,188,190
Ensembl chr 8:34,142,551...34,188,191
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
[Glyburide co-treated with Dimethyl Fumarate] inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in decreased expression of HMOX1 protein]; Glyburide inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in decreased expression of HMOX1 protein]; Glyburide inhibits the reaction [Streptozocin results in increased expression of HMOX1 mRNA] |
CTD |
PMID:30817903 PMID:36999408 |
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
EXP |
Glyburide inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Glyburide inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of IL12B protein] |
CTD |
PMID:11907163 |
|
NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797
|
|
G |
Igf1 |
insulin-like growth factor 1 |
multiple interactions |
ISO |
[Glyburide co-treated with Dimethyl Fumarate] inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of IGF1 protein]; Glyburide inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of IGF1 protein] |
CTD |
PMID:36999408 |
|
NCBI chr10:87,694,127...87,772,909
Ensembl chr10:87,694,127...87,772,904
|
|
G |
Il12b |
interleukin 12b |
multiple interactions |
EXP |
Glyburide inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of IL12B protein]; Glyburide inhibits the reaction [Lipopolysaccharides results in increased expression of IL12B protein] |
CTD |
PMID:11907163 |
|
NCBI chr11:44,290,890...44,305,504
Ensembl chr11:44,290,890...44,304,860
|
|
G |
Il17a |
interleukin 17A |
multiple interactions |
ISO |
Glyburide promotes the reaction [Isoproterenol results in increased expression of IL17A protein]; pyrvinium inhibits the reaction [Glyburide promotes the reaction [Isoproterenol results in increased expression of IL17A protein]] |
CTD |
PMID:35305975 |
|
NCBI chr 1:20,801,129...20,804,720
Ensembl chr 1:20,801,129...20,804,720
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
ISO EXP |
Glyburide inhibits the reaction [Paraquat results in increased expression of IL18 protein] Glyburide inhibits the reaction [Ozone results in increased expression of IL18 protein]; Glyburide inhibits the reaction [Paraquat results in increased secretion of IL18 protein] |
CTD |
PMID:25338942 PMID:32167222 |
|
NCBI chr 9:50,466,000...50,493,141
Ensembl chr 9:50,466,127...50,493,140
|
|
G |
Il1b |
interleukin 1 beta |
affects secretion multiple interactions |
EXP ISO |
Glyburide affects the secretion of IL1B protein Glyburide inhibits the reaction [2,5-hexanedione results in increased expression of IL1B protein]; Glyburide inhibits the reaction [Paraquat results in increased expression of IL1B protein]; Glyburide inhibits the reaction [Streptozocin results in increased expression of IL1B mRNA]; Glyburide inhibits the reaction [Streptozocin results in increased expression of IL1B protein]; Glyburide promotes the reaction [Isoproterenol results in increased expression of IL1B protein]; pyrvinium inhibits the reaction [Glyburide promotes the reaction [Isoproterenol results in increased expression of IL1B protein]] Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of IL1B protein]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B protein]; Glyburide inhibits the reaction [Ozone results in increased expression of IL1B protein]; Glyburide inhibits the reaction [Paraquat results in increased secretion of IL1B protein] |
CTD |
PMID:15578659 PMID:25338942 PMID:30817903 PMID:32167222 PMID:32375810 PMID:32522579 PMID:32860822 PMID:34052309 PMID:35305975 PMID:36504472 More...
|
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP ISO |
Glyburide inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein] Glyburide inhibits the reaction [Streptozocin results in increased expression of IL6 mRNA]; Glyburide inhibits the reaction [Streptozocin results in increased expression of IL6 protein] |
CTD |
PMID:24760747 PMID:24849676 PMID:26748309 PMID:30817903 PMID:33724628 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Ins1 |
insulin I |
multiple interactions increases secretion |
EXP ISO |
Glyburide inhibits the reaction [Nanotubes, Carbon inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; Glyburide inhibits the reaction [Streptozocin results in decreased secretion of INS1 protein] Glyburide results in increased secretion of INS1 protein Glyburide inhibits the reaction [Streptozocin results in decreased expression of INS1 protein]; Glyburide inhibits the reaction [Streptozocin results in increased expression of INS1 protein]; Glyburide inhibits the reaction [Streptozocin results in increased secretion of INS1 protein] |
CTD |
PMID:26700463 PMID:26748309 PMID:29658312 PMID:30445784 PMID:30582900 PMID:30817903 More...
|
|
NCBI chr19:52,252,735...52,253,453
Ensembl chr19:52,252,735...52,253,914
|
|
G |
Ins2 |
insulin II |
multiple interactions increases response to substance increases secretion increases expression decreases expression |
ISO |
[Glyburide co-treated with Glucose] results in increased expression of INS protein; Glyburide inhibits the reaction [Glucose results in decreased secretion of INS protein]; IRS1 protein polymorphism inhibits the reaction [Glyburide results in increased secretion of INS protein] Glyburide results in increased susceptibility to INS protein Glyburide results in increased expression of INS mRNA Glyburide results in decreased expression of INS protein |
CTD |
PMID:3116364 PMID:10430617 PMID:11305519 PMID:15642492 |
|
NCBI chr 7:142,232,393...142,233,463
Ensembl chr 7:142,232,393...142,297,118
|
|
G |
Irak1 |
interleukin-1 receptor-associated kinase 1 |
multiple interactions |
ISO |
Glyburide inhibits the reaction [Streptozocin results in increased expression of IRAK1 protein] |
CTD |
PMID:36504472 |
|
NCBI chr X:73,057,520...73,067,527
Ensembl chr X:73,057,520...73,067,524
|
|
G |
Irs1 |
insulin receptor substrate 1 |
multiple interactions |
ISO |
IRS1 protein polymorphism inhibits the reaction [Glyburide results in increased secretion of INS protein] |
CTD |
PMID:10430617 |
|
NCBI chr 1:82,210,826...82,269,160
Ensembl chr 1:82,210,822...82,269,137
|
|
G |
Irs2 |
insulin receptor substrate 2 |
multiple interactions |
ISO |
Glyburide inhibits the reaction [Streptozocin results in decreased expression of IRS2 protein] |
CTD |
PMID:33724628 |
|
NCBI chr 8:11,034,681...11,058,929
Ensembl chr 8:11,034,681...11,058,458
|
|
G |
Itgam |
integrin alpha M |
multiple interactions |
ISO |
Glyburide inhibits the reaction [2,5-hexanedione results in increased expression of ITGAM protein] |
CTD |
PMID:32522579 PMID:32860822 |
|
NCBI chr 7:127,661,812...127,717,663
Ensembl chr 7:127,661,812...127,717,663
|
|
G |
Kcnh2 |
potassium voltage-gated channel, subfamily H (eag-related), member 2 |
decreases activity |
ISO |
Glyburide results in decreased activity of KCNH2 protein |
CTD |
PMID:24052561 |
|
NCBI chr 5:24,524,583...24,556,671
Ensembl chr 5:24,524,587...24,556,602
|
|
G |
Kcnj11 |
potassium inwardly rectifying channel, subfamily J, member 11 |
multiple interactions decreases response to substance |
EXP |
Glyburide inhibits the reaction [2,4-Dinitrophenol promotes the reaction [KCNJ11 protein results in increased transport of Potassium]]; Glyburide inhibits the reaction [[Oligomycins co-treated with Deoxyglucose] results in increased activity of [KCNJ11 protein binds to ABCC9 protein]] KCNJ11 protein mutant form results in decreased susceptibility to Glyburide |
CTD |
PMID:15949470 PMID:28842488 |
|
NCBI chr 7:45,746,545...45,750,215
Ensembl chr 7:45,743,377...45,750,188
|
|
G |
Kcnj8 |
potassium inwardly-rectifying channel, subfamily J, member 8 |
decreases activity decreases response to substance |
ISO |
Glyburide results in decreased activity of KCNJ8 protein KCNJ8 protein mutant form results in decreased susceptibility to Glyburide |
CTD |
PMID:20050851 PMID:28842488 |
|
NCBI chr 6:142,510,563...142,517,340
Ensembl chr 6:142,510,563...142,517,340
|
|
G |
Kcnk18 |
potassium channel, subfamily K, member 18 |
multiple interactions |
ISO |
Glyburide inhibits the reaction [KCNK18 protein results in increased transport of Potassium] |
CTD |
PMID:12754259 |
|
NCBI chr19:59,208,080...59,225,802
Ensembl chr19:59,207,646...59,225,806
|
|
G |
Keap1 |
kelch-like ECH-associated protein 1 |
multiple interactions |
ISO |
Glyburide inhibits the reaction [Streptozocin results in decreased expression of KEAP1 mRNA] |
CTD |
PMID:30817903 |
|
NCBI chr 9:21,141,026...21,150,628
Ensembl chr 9:21,141,026...21,150,657
|
|
G |
Lyz2 |
lysozyme 2 |
decreases secretion increases secretion |
ISO |
Glyburide results in decreased secretion of LYZ protein Glyburide results in increased secretion of LYZ protein |
CTD |
PMID:15194485 PMID:15234967 |
|
NCBI chr10:117,113,446...117,118,177
Ensembl chr10:117,113,236...117,118,226
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
multiple interactions increases expression |
ISO |
Quercetin promotes the reaction [Glyburide results in increased expression of MAPK1 protein modified form] |
CTD |
PMID:20860660 |
|
NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
multiple interactions increases expression |
ISO |
Quercetin promotes the reaction [Glyburide results in increased expression of MAPK3 protein modified form] |
CTD |
PMID:20860660 |
|
NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
|
|
G |
Mbp |
myelin basic protein |
multiple interactions |
ISO |
Glyburide inhibits the reaction [2,5-hexanedione results in decreased expression of MBP protein] |
CTD |
PMID:32522579 PMID:32860822 |
|
NCBI chr18:82,492,883...82,603,762
Ensembl chr18:82,493,271...82,603,762
|
|
G |
Mir146 |
microRNA 146 |
multiple interactions |
ISO |
Glyburide inhibits the reaction [Streptozocin results in increased expression of MIR146A mRNA] |
CTD |
PMID:36504472 |
|
NCBI chr11:43,265,224...43,265,288
Ensembl chr11:43,265,224...43,265,288
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
Glyburide inhibits the reaction [Paraquat results in increased activity of MPO protein]; Glyburide promotes the reaction [Isoproterenol results in increased activity of MPO protein] |
CTD |
PMID:25338942 PMID:35305975 |
|
NCBI chr11:87,684,610...87,695,238
Ensembl chr11:87,684,407...87,695,239
|
|
G |
Mrc1 |
mannose receptor, C type 1 |
multiple interactions |
ISO |
Glyburide inhibits the reaction [2,5-hexanedione results in decreased expression of MRC1 mRNA] |
CTD |
PMID:32522579 PMID:32860822 |
|
NCBI chr 2:14,234,225...14,336,834
Ensembl chr 2:14,234,203...14,336,868
|
|
G |
Ncf1 |
neutrophil cytosolic factor 1 |
multiple interactions |
EXP |
Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NCF1 protein]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NCF1 protein] |
CTD |
PMID:32375810 PMID:34052309 |
|
NCBI chr 5:134,248,907...134,258,479
Ensembl chr 5:134,248,907...134,258,479
|
|
G |
Nefl |
neurofilament, light polypeptide |
multiple interactions |
ISO |
Glyburide inhibits the reaction [2,5-hexanedione results in decreased expression of NEFL protein] |
CTD |
PMID:32522579 PMID:32860822 |
|
NCBI chr14:68,321,312...68,326,544
Ensembl chr14:68,321,312...68,326,544
|
|
G |
Nfatc1 |
nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1 |
multiple interactions |
EXP |
Glyburide inhibits the reaction [Lipopolysaccharides affects the localization of NFATC1 protein]; Glyburide inhibits the reaction [Lipopolysaccharides promotes the reaction [NFATC1 protein binds to NOS2 promoter]] |
CTD |
PMID:27246103 |
|
NCBI chr18:80,649,418...80,756,286
Ensembl chr18:80,649,420...80,756,286
|
|
G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
multiple interactions |
ISO |
[Glyburide co-treated with Dimethyl Fumarate] inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in decreased expression of NFE2L2 protein]; Glyburide inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in decreased expression of NFE2L2 protein]; Glyburide inhibits the reaction [Streptozocin results in increased expression of NFE2L2 mRNA] |
CTD |
PMID:30817903 PMID:36999408 |
|
NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985
|
|
G |
Nfkb1 |
nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 |
multiple interactions |
ISO |
[Glyburide co-treated with Dimethyl Fumarate] inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of NFKB1 protein]; Glyburide inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of NFKB1 protein] |
CTD |
PMID:36999408 |
|
NCBI chr 3:135,290,416...135,397,422
Ensembl chr 3:135,290,416...135,397,308
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
ISO EXP |
[Glyburide co-treated with Dimethyl Fumarate] inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of NLRP3 protein]; Glyburide inhibits the reaction [2,5-hexanedione results in increased expression of NLRP3 protein]; Glyburide inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of NLRP3 protein]; Glyburide inhibits the reaction [Paraquat results in increased expression of NLRP3 protein] Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NLRP3 protein]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NLRP3 protein]; Glyburide inhibits the reaction [Ozone results in increased expression of NLRP3 protein] |
CTD |
PMID:25338942 PMID:32167222 PMID:32375810 PMID:32522579 PMID:32860822 PMID:34052309 PMID:36999408 More...
|
|
NCBI chr11:59,432,395...59,457,781
Ensembl chr11:59,432,394...59,457,782
|
|
G |
Nos2 |
nitric oxide synthase 2, inducible |
multiple interactions |
EXP ISO |
Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NOS2 mRNA]; Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NOS2 protein]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 protein]; Glyburide inhibits the reaction [Lipopolysaccharides promotes the reaction [NFATC1 protein binds to NOS2 promoter]]; Glyburide inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; Glyburide inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; Glyburide inhibits the reaction [Pinacidil inhibits the reaction [Rotenone results in increased expression of and results in increased activity of NOS2 protein]]; KN 93 inhibits the reaction [Glyburide inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]] Glyburide inhibits the reaction [2,5-hexanedione results in increased expression of NOS2 mRNA] |
CTD |
PMID:16257489 PMID:27246103 PMID:32375810 PMID:32522579 PMID:32860822 PMID:34052309 More...
|
|
NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080
|
|
G |
Nppb |
natriuretic peptide type B |
multiple interactions |
ISO |
Glyburide inhibits the reaction [natakalim inhibits the reaction [Isoproterenol results in increased expression of NPPB mRNA]]; Glyburide inhibits the reaction [natakalim inhibits the reaction [Isoproterenol results in increased expression of NPPB protein]] |
CTD |
PMID:27890915 |
|
NCBI chr 4:148,070,264...148,071,662
Ensembl chr 4:148,070,245...148,071,662
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
decreases expression |
ISO |
Glyburide results in decreased expression of NR1H4 mRNA |
CTD |
PMID:28391356 |
|
NCBI chr10:89,290,096...89,369,484
Ensembl chr10:89,290,096...89,369,447
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1, cytosolic |
multiple interactions |
ISO |
Glyburide inhibits the reaction [Streptozocin results in increased expression of PCK1 mRNA] |
CTD |
PMID:20363216 |
|
NCBI chr 2:172,994,866...173,001,067
Ensembl chr 2:172,994,841...173,001,066
|
|
G |
Pklr |
pyruvate kinase liver and red blood cell |
multiple interactions |
ISO |
Glyburide inhibits the reaction [Streptozocin results in decreased expression of PKLR mRNA] |
CTD |
PMID:20363216 |
|
NCBI chr 3:89,043,429...89,054,122
Ensembl chr 3:89,043,449...89,054,091
|
|
G |
Pparg |
peroxisome proliferator activated receptor gamma |
multiple interactions |
ISO |
Glyburide inhibits the reaction [Streptozocin results in decreased expression of PPARG mRNA]; Glyburide inhibits the reaction [Streptozocin results in decreased expression of PPARG protein] |
CTD |
PMID:29223569 |
|
NCBI chr 6:115,337,828...115,467,365
Ensembl chr 6:115,337,912...115,467,360
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
Glyburide inhibits the reaction [Streptozocin results in increased expression of PTGS2 mRNA] |
CTD |
PMID:30817903 |
|
NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978
|
|
G |
Pycard |
PYD and CARD domain containing |
multiple interactions |
ISO |
Glyburide inhibits the reaction [Paraquat results in increased expression of PYCARD protein] |
CTD |
PMID:25338942 |
|
NCBI chr 7:127,590,545...127,593,039
Ensembl chr 7:127,588,880...127,593,039
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
multiple interactions |
ISO |
Glyburide inhibits the reaction [Streptozocin results in increased expression of RELA mRNA]; Glyburide inhibits the reaction [Streptozocin results in increased expression of RELA protein] |
CTD |
PMID:33724628 PMID:36504472 |
|
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
|
|
G |
Slc10a1 |
solute carrier family 10 (sodium/bile acid cotransporter family), member 1 |
decreases expression multiple interactions |
ISO EXP |
Glyburide results in decreased expression of SLC10A1 mRNA [Bile Acids and Salts co-treated with Glyburide] results in decreased expression of SLC10A1 mRNA |
CTD |
PMID:27765674 PMID:28391356 PMID:35708773 |
|
NCBI chr12:80,999,959...81,015,479
Ensembl chr12:80,999,957...81,015,479
|
|
G |
Slc2a2 |
solute carrier family 2 (facilitated glucose transporter), member 2 |
multiple interactions |
ISO |
Glyburide inhibits the reaction [Streptozocin results in decreased expression of SLC2A2 protein] |
CTD |
PMID:33724628 |
|
NCBI chr 3:28,752,052...28,782,510
Ensembl chr 3:28,752,052...28,785,508
|
|
G |
Slc2a4 |
solute carrier family 2 (facilitated glucose transporter), member 4 |
multiple interactions |
ISO |
Glyburide inhibits the reaction [Streptozocin results in decreased expression of SLC2A4 mRNA]; Glyburide inhibits the reaction [Streptozocin results in decreased expression of SLC2A4 protein] |
CTD |
PMID:29223569 PMID:33724628 |
|
NCBI chr11:69,833,112...69,839,040
Ensembl chr11:69,833,365...69,839,014
|
|
G |
Slc6a3 |
solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 |
multiple interactions |
EXP |
Glyburide promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC6A3 protein] |
CTD |
PMID:16725203 |
|
NCBI chr13:73,684,270...73,726,791
Ensembl chr13:73,684,866...73,726,791
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family, member 1b2 |
multiple interactions |
ISO |
Glyburide inhibits the reaction [SLCO1B3 protein results in increased uptake of Atorvastatin] |
CTD |
PMID:23121773 |
|
NCBI chr 6:141,575,178...141,632,372
Ensembl chr 6:141,575,244...141,632,372
|
|
G |
Slco2b1 |
solute carrier organic anion transporter family, member 2b1 |
multiple interactions |
ISO |
Glyburide inhibits the reaction [SLCO2B1 protein results in increased uptake of Atorvastatin] |
CTD |
PMID:23121773 |
|
NCBI chr 7:99,307,011...99,360,547
Ensembl chr 7:99,307,011...99,360,547
|
|
G |
Snca |
synuclein, alpha |
multiple interactions |
EXP |
Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased phosphorylation of SNCA protein]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] promotes the reaction [SNCA protein binds to SNCA protein]]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of SNCA protein] |
CTD |
PMID:32375810 PMID:34052309 |
|
NCBI chr 6:60,708,557...60,806,839
Ensembl chr 6:60,708,559...60,806,839
|
|
G |
Sod1 |
superoxide dismutase 1, soluble |
multiple interactions |
ISO |
[Glyburide co-treated with Dimethyl Fumarate] inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in decreased expression of SOD1 protein]; Glyburide inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in decreased expression of SOD1 protein] |
CTD |
PMID:36999408 |
|
NCBI chr16:90,017,650...90,023,221
Ensembl chr16:90,017,642...90,023,217
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
Glyburide promotes the reaction [Isoproterenol results in increased expression of TGFB1 protein]; pyrvinium inhibits the reaction [Glyburide promotes the reaction [Isoproterenol results in increased expression of TGFB1 protein]] |
CTD |
PMID:35305975 |
|
NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502
|
|
G |
Th |
tyrosine hydroxylase |
multiple interactions |
EXP |
Glyburide promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein] |
CTD |
PMID:16725203 |
|
NCBI chr 7:142,446,516...142,453,732
Ensembl chr 7:142,446,489...142,484,865
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
ISO |
Glyburide inhibits the reaction [Streptozocin results in increased expression of TLR4 protein] |
CTD |
PMID:36504472 |
|
NCBI chr 4:66,745,788...66,765,338
Ensembl chr 4:66,745,821...66,848,521
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP ISO |
Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TNF mRNA]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TNF mRNA]; Glyburide inhibits the reaction [Pinacidil inhibits the reaction [Rotenone results in increased secretion of TNF protein]] Glyburide inhibits the reaction [2,5-hexanedione results in increased expression of TNF mRNA]; Glyburide inhibits the reaction [Streptozocin results in increased expression of TNF mRNA]; Glyburide inhibits the reaction [Streptozocin results in increased expression of TNF protein]; Glyburide promotes the reaction [Isoproterenol results in increased expression of TNF protein]; pyrvinium inhibits the reaction [Glyburide promotes the reaction [Isoproterenol results in increased expression of TNF protein]] |
CTD |
PMID:16257489 PMID:24760747 PMID:26748309 PMID:30817903 PMID:32375810 PMID:32522579 PMID:32860822 PMID:33724628 PMID:34052309 PMID:35305975 PMID:36504472 More...
|
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Tnni3 |
troponin I, cardiac 3 |
multiple interactions |
ISO |
Glyburide promotes the reaction [Isoproterenol results in increased expression of TNNI3 protein]; pyrvinium inhibits the reaction [Glyburide promotes the reaction [Isoproterenol results in increased expression of TNNI3 protein]] |
CTD |
PMID:35305975 |
|
NCBI chr 7:4,521,304...4,526,228
Ensembl chr 7:4,521,304...4,527,228
|
|
G |
Traf6 |
TNF receptor-associated factor 6 |
multiple interactions |
ISO |
Glyburide inhibits the reaction [Streptozocin results in increased expression of TRAF6 protein] |
CTD |
PMID:36504472 |
|
NCBI chr 2:101,508,765...101,532,013
Ensembl chr 2:101,508,774...101,532,014
|
|
G |
Trp53 |
transformation related protein 53 |
multiple interactions increases expression |
ISO |
Glyburide inhibits the reaction [Streptozocin results in increased expression of TP53 mRNA]; Glyburide inhibits the reaction [Streptozocin results in increased expression of TP53 protein] Glyburide results in increased expression of TP53 mRNA |
CTD |
PMID:30817903 PMID:33387473 PMID:33652124 |
|
NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699
|
|
G |
Trpm4 |
transient receptor potential cation channel, subfamily M, member 4 |
decreases activity |
ISO EXP |
Glyburide results in decreased activity of TRPM4 protein |
CTD |
PMID:16966582 PMID:17188667 |
|
NCBI chr 7:44,952,579...44,983,495
Ensembl chr 7:44,952,056...44,983,204
|
|
G |
Xdh |
xanthine dehydrogenase |
multiple interactions |
EXP |
[Glyburide results in decreased activity of ABCC9 protein] which results in increased expression of XDH protein |
CTD |
PMID:22622455 |
|
NCBI chr17:74,190,890...74,257,191
Ensembl chr17:74,190,890...74,257,191
|
|
|
G |
Ahr |
aryl-hydrocarbon receptor |
multiple interactions |
ISO |
metsulfuron methyl binds to and results in increased activity of AHR protein |
CTD |
PMID:14636698 |
|
NCBI chr12:35,547,978...35,584,988
Ensembl chr12:35,547,973...35,585,037
|
|
G |
Odc1 |
ornithine decarboxylase, structural 1 |
decreases expression |
ISO |
metsulfuron methyl results in decreased expression of ODC1 mRNA |
CTD |
PMID:15519604 |
|
NCBI chr12:17,594,906...17,601,503
Ensembl chr12:17,594,795...17,601,506
|
|
|
G |
Ins1 |
insulin I |
increases response to substance |
ISO |
Tolazamide results in increased susceptibility to INS1 protein |
CTD |
PMID:6337899 |
|
NCBI chr19:52,252,735...52,253,453
Ensembl chr19:52,252,735...52,253,914
|
|
|
G |
Abcb1a |
ATP-binding cassette, sub-family B member 1A |
decreases activity multiple interactions |
ISO |
Tolbutamide results in decreased activity of ABCB1 protein Tolbutamide inhibits the reaction [ABCB1 protein results in increased uptake of quinidinium] |
CTD |
PMID:32305507 |
|
NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575
|
|
G |
Abcc8 |
ATP-binding cassette, sub-family C member 8 |
multiple interactions |
ISO |
[KCNJ11 mutant form co-treated with ABCC8 mutant form] results in decreased susceptibility to Tolbutamide; ABCC8 gene SNP inhibits the reaction [Tolbutamide results in increased secretion of INS protein]; Tolbutamide inhibits the reaction [ABCC8 protein mutant form results in increased activity of KCNJ11 protein] |
CTD |
PMID:9568693 PMID:18025464 PMID:22209866 |
|
NCBI chr 7:45,753,952...45,829,441
Ensembl chr 7:45,753,947...45,829,457
|
|
G |
Alb |
albumin |
affects binding |
ISO |
Tolbutamide binds to ALB protein |
CTD |
PMID:19596536 PMID:20435530 PMID:20956006 PMID:20974553 |
|
NCBI chr 5:90,608,729...90,624,461
Ensembl chr 5:90,608,756...90,624,461
|
|
G |
Ccnd1 |
cyclin D1 |
increases expression |
ISO |
Tolbutamide results in increased expression of CCND1 protein |
CTD |
PMID:16718685 |
|
NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662
|
|
G |
Ccnd3 |
cyclin D3 |
increases expression |
ISO |
Tolbutamide results in increased expression of CCND3 protein |
CTD |
PMID:16718685 |
|
NCBI chr17:47,815,976...47,910,614
Ensembl chr17:47,815,976...47,910,616
|
|
G |
Cdkn1a |
cyclin dependent kinase inhibitor 1A |
multiple interactions increases expression |
ISO |
GJA1 promotes the reaction [Tolbutamide results in increased expression of CDKN1A protein] |
CTD |
PMID:16718685 |
|
NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701
|
|
G |
Cdkn1b |
cyclin dependent kinase inhibitor 1B |
increases expression |
ISO |
Tolbutamide results in increased expression of CDKN1B protein |
CTD |
PMID:16718685 |
|
NCBI chr 6:134,897,364...134,902,488
Ensembl chr 6:134,897,364...134,902,476
|
|
G |
Cyp2c23 |
cytochrome P450, family 2, subfamily c, polypeptide 23 |
increases metabolic processing multiple interactions |
EXP |
CYP2C23 protein results in increased metabolism of Tolbutamide [CYP2C23 protein results in increased metabolism of Tolbutamide] which results in increased chemical synthesis of 4'-hydroxytolbutamide |
CTD |
PMID:30503582 |
|
NCBI chr19:43,993,461...44,017,695
Ensembl chr19:43,993,461...44,017,647
|
|
G |
Cyp2c29 |
cytochrome P450, family 2, subfamily c, polypeptide 29 |
increases hydroxylation |
ISO |
CYP2C8 protein results in increased hydroxylation of Tolbutamide |
CTD |
PMID:15843491 |
|
NCBI chr19:39,275,541...39,319,157
Ensembl chr19:39,257,849...39,319,157
|
|
G |
Cyp2c38 |
cytochrome P450, family 2, subfamily c, polypeptide 38 |
increases metabolic processing multiple interactions increases hydroxylation |
ISO |
CYP2C19 protein results in increased metabolism of Tolbutamide [CYP2C19 protein results in increased hydroxylation of Tolbutamide] which results in increased chemical synthesis of 4'-hydroxytolbutamide |
CTD |
PMID:18511451 PMID:30500380 |
|
NCBI chr19:39,379,109...39,451,519
Ensembl chr19:39,378,000...39,451,519
|
|
G |
Cyp2c39 |
cytochrome P450, family 2, subfamily c, polypeptide 39 |
multiple interactions increases metabolic processing |
EXP |
[CYP2C39 protein results in increased metabolism of Tolbutamide] which results in increased chemical synthesis of 4'-hydroxytolbutamide |
CTD |
PMID:30503582 |
|
NCBI chr19:39,335,790...39,558,012
Ensembl chr19:39,499,306...39,556,973
|
|
G |
Cyp2c40 |
cytochrome P450, family 2, subfamily c, polypeptide 40 |
increases metabolic processing multiple interactions |
EXP |
CYP2C40 protein results in increased metabolism of Tolbutamide [CYP2C40 protein results in increased metabolism of Tolbutamide] which results in increased chemical synthesis of 4'-hydroxytolbutamide |
CTD |
PMID:30503582 |
|
NCBI chr19:39,755,517...39,801,258
Ensembl chr19:39,755,515...39,801,258
|
|
G |
Cyp2c50 |
cytochrome P450, family 2, subfamily c, polypeptide 50 |
increases metabolic processing multiple interactions |
EXP |
CYP2C50 protein results in increased metabolism of Tolbutamide [CYP2C50 protein results in increased metabolism of Tolbutamide] which results in increased chemical synthesis of 4'-hydroxytolbutamide |
CTD |
PMID:30503582 |
|
NCBI chr19:40,078,123...40,102,399
Ensembl chr19:40,078,132...40,102,394
|
|
G |
Cyp2c52-ps |
cytochrome P450, family 2, subfamily c, polypeptide 52, pseudogene |
increases metabolic processing |
ISO |
CYP2C18 results in increased metabolism of Tolbutamide |
CTD |
PMID:15301741 |
|
NCBI chr19:38,965,106...38,992,071
Ensembl chr19:38,965,091...38,991,733
|
|
G |
Cyp2c54 |
cytochrome P450, family 2, subfamily c, polypeptide 54 |
increases metabolic processing multiple interactions |
EXP |
CYP2C54 protein results in increased metabolism of Tolbutamide [CYP2C54 protein results in increased metabolism of Tolbutamide] which results in increased chemical synthesis of 4'-hydroxytolbutamide |
CTD |
PMID:30503582 |
|
NCBI chr19:40,026,383...40,062,289
Ensembl chr19:40,026,384...40,062,271
|
|
G |
Cyp2c55 |
cytochrome P450, family 2, subfamily c, polypeptide 55 |
multiple interactions increases metabolic processing |
EXP |
[CYP2C55 protein results in increased metabolism of Tolbutamide] which results in increased chemical synthesis of 4'-hydroxytolbutamide |
CTD |
PMID:30503582 |
|
NCBI chr19:38,995,384...39,031,134
Ensembl chr19:38,995,463...39,031,137
|
|
G |
Cyp2c65 |
cytochrome P450, family 2, subfamily c, polypeptide 65 |
decreases hydroxylation increases metabolic processing multiple interactions increases hydroxylation increases hydrolysis affects hydroxylation affects metabolic processing decreases metabolic processing increases chemical synthesis |
ISO EXP |
CYP2C9 gene SNP results in decreased hydroxylation of Tolbutamide CYP2C65 protein results in increased metabolism of Tolbutamide [CYP2C65 protein results in increased metabolism of Tolbutamide] which results in increased chemical synthesis of 4'-hydroxytolbutamide CYP2C9 protein results in increased hydroxylation of Tolbutamide [CYP2C9 protein results in increased metabolism of Tolbutamide] which results in increased chemical synthesis of 4'-hydroxytolbutamide; Acetone promotes the reaction [CYP2C9 protein results in increased hydroxylation of Tolbutamide]; acetonitrile promotes the reaction [CYP2C9 protein results in increased hydroxylation of Tolbutamide]; CYP2C9 gene mutant form inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Tolbutamide]; CYP2C9 protein binds to and affects the metabolism of Tolbutamide; Fenitrothion inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Tolbutamide]; Malathion inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Tolbutamide]; phenthoate inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Tolbutamide]; pranlukast inhibits the reaction [CYP2C9 protein results in increased metabolism of Tolbutamide]; profenofos inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Tolbutamide]; Sulfaphenazole inhibits the reaction [CYP2C9 protein results in increased hydrolysis of Tolbutamide]; Sulfaphenazole inhibits the reaction [CYP2C9 protein results in increased metabolism of Tolbutamide]; Ticlopidine inhibits the reaction [CYP2C9 protein results in increased metabolism of Tolbutamide]; Tolbutamide inhibits the reaction [CYP2C9 protein affects the metabolism of Diclofenac]; zafirlukast inhibits the reaction [CYP2C9 protein results in increased metabolism of Tolbutamide] CYP2C9 protein affects the hydroxylation of Tolbutamide CYP2C9 gene polymorphism affects the metabolism of Tolbutamide; CYP2C9 gene SNP affects the metabolism of Tolbutamide; CYP2C9 protein affects the metabolism of Tolbutamide CYP2C9 gene polymorphism results in decreased metabolism of Tolbutamide CYP2C9 protein results in increased chemical synthesis of Tolbutamide metabolite |
CTD |
PMID:2025243 PMID:9110362 PMID:9170147 PMID:9522436 PMID:10208645 PMID:10611138 PMID:11377097 PMID:11875364 PMID:12426520 PMID:12433797 PMID:12464242 PMID:12467917 PMID:15045499 PMID:15155557 PMID:15327588 PMID:15370959 PMID:15626586 PMID:15843491 PMID:15856409 PMID:16081671 PMID:16124035 PMID:17267297 PMID:17565714 PMID:17702393 PMID:19082874 PMID:19715737 PMID:21915887 PMID:22634058 PMID:23850985 PMID:25994031 PMID:26255664 PMID:26763401 PMID:30503582 PMID:32198085 More...
|
|
NCBI chr19:39,049,450...39,082,392
Ensembl chr19:39,049,459...39,082,388
|
|
G |
Cyp2c66 |
cytochrome P450, family 2, subfamily c, polypeptide 66 |
multiple interactions increases metabolic processing |
EXP |
[CYP2C66 protein results in increased metabolism of Tolbutamide] which results in increased chemical synthesis of 4'-hydroxytolbutamide |
CTD |
PMID:30503582 |
|
NCBI chr19:39,102,342...39,175,200
Ensembl chr19:39,102,342...39,175,516
|
|
G |
Cyp2c67 |
cytochrome P450, family 2, subfamily c, polypeptide 67 |
increases metabolic processing multiple interactions |
EXP |
CYP2C67 protein results in increased metabolism of Tolbutamide [CYP2C67 protein results in increased metabolism of Tolbutamide] which results in increased chemical synthesis of 4'-hydroxytolbutamide |
CTD |
PMID:30503582 |
|
NCBI chr19:39,597,288...39,637,497
Ensembl chr19:39,597,286...39,637,495
|
|
G |
Cyp2c68 |
cytochrome P450, family 2, subfamily c, polypeptide 68 |
multiple interactions increases metabolic processing |
EXP |
[CYP2C68 protein results in increased metabolism of Tolbutamide] which results in increased chemical synthesis of 4'-hydroxytolbutamide |
CTD |
PMID:30503582 |
|
NCBI chr19:39,677,280...39,729,545
Ensembl chr19:39,677,278...39,729,498
|
|
G |
Cyp2c69 |
cytochrome P450, family 2, subfamily c, polypeptide 69 |
multiple interactions increases metabolic processing |
EXP |
[CYP2C69 protein results in increased metabolism of Tolbutamide] which results in increased chemical synthesis of 4'-hydroxytolbutamide |
CTD |
PMID:30503582 |
|
NCBI chr19:39,831,104...39,875,213
Ensembl chr19:39,831,258...39,875,243
|
|
G |
Cyp2c70 |
cytochrome P450, family 2, subfamily c, polypeptide 70 |
increases metabolic processing multiple interactions |
EXP |
CYP2C70 protein results in increased metabolism of Tolbutamide [CYP2C70 protein results in increased metabolism of Tolbutamide] which results in increased chemical synthesis of 4'-hydroxytolbutamide |
CTD |
PMID:30503582 |
|
NCBI chr19:40,141,805...40,175,730
Ensembl chr19:40,141,797...40,175,777
|
|
G |
Gcg |
glucagon |
increases secretion |
ISO |
Tolbutamide results in increased secretion of GCG protein |
CTD |
PMID:15919803 |
|
NCBI chr 2:62,304,874...62,313,997
Ensembl chr 2:62,304,874...62,313,994
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
multiple interactions increases expression |
ISO |
GJA1 promotes the reaction [Tolbutamide results in increased expression of CDKN1A protein]; Tolbutamide promotes the reaction [Bucladesine results in increased expression of GJA1 protein] Tolbutamide results in increased expression of GJA1 protein |
CTD |
PMID:11741589 PMID:16718685 |
|
NCBI chr10:56,253,297...56,266,519
Ensembl chr10:56,253,426...56,278,609
|
|
G |
Hk1 |
hexokinase 1 |
increases expression |
EXP |
Tolbutamide results in increased expression of HK1 protein |
CTD |
PMID:11835228 |
|
NCBI chr10:62,104,634...62,215,699
Ensembl chr10:62,104,634...62,215,687
|
|
G |
Ins1 |
insulin I |
affects secretion multiple interactions |
EXP |
Tolbutamide affects the secretion of INS1 protein [Tolbutamide co-treated with FR900359] inhibits the reaction [Glucose results in increased secretion of INS1 protein]; Tolbutamide inhibits the reaction [arsenite inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; Tolbutamide inhibits the reaction [dimethylarsinous acid inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; Tolbutamide inhibits the reaction [methylarsonite inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; Tolbutamide promotes the reaction [Glucose results in increased secretion of INS1 protein] |
CTD |
PMID:9366569 PMID:31332465 PMID:37217659 |
|
NCBI chr19:52,252,735...52,253,453
Ensembl chr19:52,252,735...52,253,914
|
|
G |
Ins2 |
insulin II |
multiple interactions increases secretion |
ISO |
ABCC8 gene SNP inhibits the reaction [Tolbutamide results in increased secretion of INS protein] |
CTD |
PMID:9032110 PMID:9568693 |
|
NCBI chr 7:142,232,393...142,233,463
Ensembl chr 7:142,232,393...142,297,118
|
|
G |
Kcnj11 |
potassium inwardly rectifying channel, subfamily J, member 11 |
multiple interactions decreases activity |
ISO |
[KCNJ11 mutant form co-treated with ABCC8 mutant form] results in decreased susceptibility to Tolbutamide; Tolbutamide inhibits the reaction [ABCC8 protein mutant form results in increased activity of KCNJ11 protein] Tolbutamide results in decreased activity of KCNJ11 protein |
CTD |
PMID:18025464 PMID:22209866 |
|
NCBI chr 7:45,746,545...45,750,215
Ensembl chr 7:45,743,377...45,750,188
|
|
G |
Mki67 |
antigen identified by monoclonal antibody Ki 67 |
decreases expression |
ISO |
Tolbutamide results in decreased expression of MKI67 protein |
CTD |
PMID:16718685 |
|
NCBI chr 7:135,291,513...135,318,286
Ensembl chr 7:135,291,513...135,318,090
|
|
G |
Pdcd4 |
programmed cell death 4 |
decreases expression increases expression |
ISO |
Tolbutamide results in decreased expression of PDCD4 mRNA Tolbutamide results in increased expression of PDCD4 mRNA |
CTD |
PMID:21873647 |
|
NCBI chr19:53,880,662...53,926,024
Ensembl chr19:53,880,662...53,918,291
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
decreases phosphorylation |
ISO |
Tolbutamide results in decreased phosphorylation of RB1 protein |
CTD |
PMID:16718685 |
|
NCBI chr14:73,430,298...73,563,446
Ensembl chr14:73,421,113...73,563,262
|
|
G |
Slc2a1 |
solute carrier family 2 (facilitated glucose transporter), member 1 |
increases expression |
EXP |
Tolbutamide results in increased expression of SLC2A1 mRNA; Tolbutamide results in increased expression of SLC2A1 protein |
CTD |
PMID:2682625 PMID:11835228 |
|
NCBI chr 4:118,966,001...118,994,527
Ensembl chr 4:118,965,908...118,995,180
|
|
G |
Tnfaip3 |
tumor necrosis factor, alpha-induced protein 3 |
decreases expression |
ISO |
Tolbutamide results in decreased expression of TNFAIP3 mRNA |
CTD |
PMID:21873647 |
|
NCBI chr10:18,876,658...18,891,158
Ensembl chr10:18,876,658...18,891,405
|
|
G |
Tpd52 |
tumor protein D52 |
decreases expression increases expression |
ISO |
Tolbutamide results in decreased expression of TPD52 mRNA Tolbutamide results in increased expression of TPD52 mRNA |
CTD |
PMID:21873647 |
|
NCBI chr 3:8,991,590...9,069,824
Ensembl chr 3:8,990,653...9,069,783
|
|
G |
Trp53 |
transformation related protein 53 |
increases expression |
ISO |
Tolbutamide results in increased expression of TP53 mRNA |
CTD |
PMID:16426753 |
|
NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699
|
|
G |
Ugdh |
UDP-glucose dehydrogenase |
decreases expression |
ISO |
Tolbutamide results in decreased expression of UGDH protein |
CTD |
PMID:4270849 |
|
NCBI chr 5:65,570,550...65,593,185
Ensembl chr 5:65,570,564...65,593,292
|
|
|
G |
Agt |
angiotensinogen |
increases expression |
ISO |
Torsemide results in increased expression of AGT protein modified form |
CTD |
PMID:18154949 |
|
NCBI chr 8:125,283,326...125,296,445
Ensembl chr 8:125,283,273...125,296,445
|
|
G |
Cyp11b2 |
cytochrome P450, family 11, subfamily b, polypeptide 2 |
affects expression |
ISO |
Torsemide affects the expression of CYP11B2 protein |
CTD |
PMID:18001696 |
|
NCBI chr15:74,722,467...74,728,080
Ensembl chr15:74,722,859...74,728,167
|
|
G |
Cyp2c29 |
cytochrome P450, family 2, subfamily c, polypeptide 29 |
increases metabolic processing multiple interactions |
ISO |
CYP2C8 protein results in increased metabolism of Torsemide Torsemide inhibits the reaction [Amiodarone results in decreased activity of CYP2C8 protein]; Torsemide inhibits the reaction [Fluoxetine results in decreased activity of CYP2C8 protein]; Torsemide inhibits the reaction [Isoniazid results in decreased activity of CYP2C8 protein]; Torsemide inhibits the reaction [Nortriptyline results in decreased activity of CYP2C8 protein]; Torsemide inhibits the reaction [Phenelzine results in decreased activity of CYP2C8 protein]; Torsemide inhibits the reaction [Verapamil results in decreased activity of CYP2C8 protein] |
CTD |
PMID:15304522 |
|
NCBI chr19:39,275,541...39,319,157
Ensembl chr19:39,257,849...39,319,157
|
|
G |
Cyp2c52-ps |
cytochrome P450, family 2, subfamily c, polypeptide 52, pseudogene |
affects metabolic processing |
ISO |
CYP2C11 protein affects the metabolism of Torsemide |
CTD |
PMID:15890479 |
|
NCBI chr19:38,965,106...38,992,071
Ensembl chr19:38,965,091...38,991,733
|
|
G |
Cyp2c65 |
cytochrome P450, family 2, subfamily c, polypeptide 65 |
increases hydroxylation increases metabolic processing |
ISO |
CYP2C9 protein results in increased hydroxylation of Torsemide CYP2C9 protein results in increased metabolism of Torsemide |
CTD |
PMID:9110362 PMID:19082874 |
|
NCBI chr19:39,049,450...39,082,392
Ensembl chr19:39,049,459...39,082,388
|
|
G |
Nppa |
natriuretic peptide type A |
decreases expression |
ISO |
Torsemide results in decreased expression of NPPA protein |
CTD |
PMID:18154949 |
|
NCBI chr 4:148,085,179...148,086,531
Ensembl chr 4:148,085,179...148,086,536
|
|
G |
Nr3c2 |
nuclear receptor subfamily 3, group C, member 2 |
multiple interactions |
ISO |
Torsemide inhibits the reaction [Aldosterone binds to NR3C2 protein] |
CTD |
PMID:7954537 |
|
NCBI chr 8:77,626,422...77,971,641
Ensembl chr 8:77,626,070...77,971,641
|
|
G |
Ren1 |
renin 1 structural |
increases expression |
ISO |
Torsemide results in increased expression of REN protein |
CTD |
PMID:7954537 |
|
NCBI chr 1:133,278,412...133,288,058
Ensembl chr 1:133,278,248...133,288,063
|
|
G |
Slc12a2 |
solute carrier family 12, member 2 |
decreases activity multiple interactions |
ISO |
Torsemide results in decreased activity of SLC12A2 protein Torsemide inhibits the reaction [SLC12A2 protein results in increased uptake of Rubidium] |
CTD |
PMID:29959396 |
|
NCBI chr18:58,011,505...58,079,893
Ensembl chr18:58,011,750...58,079,893
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
affects expression decreases expression |
ISO |
Torsemide affects the expression of TGFB1 protein Torsemide results in decreased expression of TGFB1 protein |
CTD |
PMID:18001696 PMID:18154949 |
|
NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502
|
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
[prochloraz co-treated with Chlorpyrifos co-treated with triflusulfuron-methyl] results in increased expression of CYP19A1 mRNA |
CTD |
PMID:25233012 |
|
NCBI chr 9:54,073,221...54,175,448
Ensembl chr 9:54,073,221...54,175,394
|
|